Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
C. albicans
C. glabrata
C. parapsilosis
Candida spp.
PAFE
antifungal
antifungal activity
echinocandin
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
23
06
2022
received:
28
02
2022
accepted:
26
06
2022
pubmed:
3
7
2022
medline:
12
10
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
Rezafungin, a new echinocandin with an extended half-life, exhibits potent activity against Candida spp. Aside from the MIC, specific interactions between antifungal and isolate, including the duration of anti-infective activity, may impact dose interval choices and infection outcome. We evaluated rezafungin and micafungin post-antifungal effect (PAFE) against C. albicans, C. parapsilosis and C. glabrata. Six Candida spp. isolates were tested, including two of each species, C. albicans, C. parapsilosis and C. glabrata. Antifungal susceptibility testing was performed using the CLSI reference broth microdilution method. Antifungal concentrations of 1x, 4x and 16x the baseline MIC were used for PAFE determinations. Colony counts were performed at T0 (pre-exposure), after the 1-h drug exposure, after the cell wash (T1), and at T2, T4, T8, T12, T24 and T48 h. Rezafungin PAFE results were equivalent to micafungin PAFE values for one C. albicans (>14.9 h) and both C. glabrata (>40 h) isolates for all concentrations tested. The rezafungin and micafungin PAFEs could not be determined against one C. albicans isolate. Prolonged PAFE results were also noted for rezafungin (range, 18.4 to >40 h) against both C. parapsilosis isolates at all concentrations, while no micafungin PAFE or a short PAFE (range, 1.8 to 7.4 h) was observed against these organisms, except at 16x bMIC. Rezafungin showed sustained growth inhibition following drug removal and displayed equivalent or longer PAFE values than micafungin against all tested Candida spp.
Substances chimiques
Antifungal Agents
0
Echinocandins
0
Rezafungin
G013B5478J
Micafungin
R10H71BSWG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1040-1044Subventions
Organisme : Cidara Therapeutics
Informations de copyright
© 2022 Wiley-VCH GmbH.
Références
Rauseo AM, Coler-Reilly A, Larson L, Spec A. Hope on the horizon: novel fungal treatments in development. Open Forum Infect Dis. 2020;7(2):ofaa016. doi:10.1093/ofid/ofaa016
Gonzalez-Lara MF, Sifuentes-Osornio J, Ostrosky-Zeichner L. Drugs in clinical development for fungal infections. Drugs. 2017;77(14):1505-1518. doi:10.1007/s40265-017-0805-2
Kofla G, Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur J Med Res. 2011;16(4):159-166. doi:10.1186/2047-783x-16-4-159
Pfaller MA, Carvalhaes C, Messer SA, Rhomberg PR, Castanheira M. Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (Sentry Program, 2016 to 2018). Antimicrob Agents Chemother. 2020;64(4):e00099-20. doi:10.1128/AAC.00099-20
Carvalhaes CG, Klauer AL, Rhomberg PR, Pfaller MA, Castanheira M. Activity of rezafugin and comparator antifungal agents tested against a worldwide collection of contemporaneous invasive fungal isolates (2019-2020). 2021. Poster #1068771
Gumbo T. Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr Opin Infect Dis. 2007;20(6):587-591. doi:10.1097/QCO.0b013e3282f1bea3
Smith RP, Baltch A, Bopp LH, Ritz WJ, Michelsen PP. Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis. Diagn Microbiol Infect Dis. 2011;71(2):131-138. doi:10.1016/j.diagmicrobio.2011.06.018
Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000;44(4):1108-1111. doi:10.1128/AAC.44.4.1108-1111.2000
Locke JB, Almaguer AL, Zuill DE, Bartizal K. Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida Species. Antimicrob Agents Chemother. 2016;60(10):6100-6107. doi:10.1128/AAC.00620-16
Zhao Y, Perez WB, Jimenez-Ortigosa C, et al. CD101: a novel long-acting echinocandin. Cell Microbiol. 2016;18(9):1308-1316. doi:10.1111/cmi.12640
Hall D, Bonifas R, Stapert L, Thwaites M, Shinabarger DL, Pillar CM. In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp. Diagn Microbiol Infect Dis. 2017;89(3):20-211. doi:10.1016/j.diagmicrobio.2017.07.007
Nguyen KT, Ta P, Hoang BT, et al. Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates. Int J Antimicrob Agents. 2010;35(1):80-84. doi:10.1016/j.ijantimicag.2009.09.003
Clancy CJ, Huang H, Cheng S, Derendorf H, Nguyen MH. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother. 2006;50(7):2569-2572. doi:10.1128/AAC.00291-06
Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother. 2003;47(4):1179-1186. doi:10.1128/AAC.47.4.1179-1186.2003
Gil-Alonso S, Quindos G, Eraso E, Jauregizar N. Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis. Rev Esp Quimioter. 2019;32(2):183-188.
Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a Phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE Trial. Clin Infect Dis. 2020;73(11):e3647-e3655. doi:10.1093/cid/ciaa1380